Completed PHASE3 INTERVENTIONAL 1-arm NCT05989126

Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)

A Study in Patients With Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration to Evaluate a High Dose Aflibercept (8 mg) Prefilled Syringe

Sponsor: Regeneron Pharmaceuticals

Conditions Diabetic Macular Edema (DME) Neovascular Age-Related Macular Degeneration (nAMD)

Interventions aflibercept 8 mg PFS

Updated 7 times since 2023 Last updated: May 29, 2025 Started: Apr 15, 2024 Primary completion: May 31, 2024 Completion: May 31, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Diabetic Macular Edema (DME) and Neovascular Age-Related Macular Degeneration (nAMD), this trial is completed. The trial is conducted by Regeneron Pharmaceuticals and has accumulated 7 data snapshots since 2024. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Jun 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Jun 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Jun 2024 — Jul 2024 [monthly]

Active Not Recruiting PHASE3

Status: Not Yet Recruiting → Active Not Recruiting
Apr 2024 — Jun 2024 [monthly]

Not Yet Recruiting PHASE3

▶ Show 2 earlier versions

Dec 2023 — Apr 2024 [monthly]

Not Yet Recruiting PHASE3
Sep 2023 — Dec 2023 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Regeneron Pharmaceuticals

Data source: Regeneron Pharmaceuticals

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bellaire, United States
• The Woodlands, United States